Company Filing History:
1 out of 987 
1 out of 49 
1 out of 2 Years Active: 2015
Title: Keisuke Narukawa: Innovator in Therapeutic Oligonucleotides
Introduction
Keisuke Narukawa is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic agents for dyslipidemia. His innovative work focuses on oligonucleotides that target specific genes, showcasing his expertise in genetic research and therapeutic applications.
Latest Patents
Narukawa holds a patent for an oligonucleotide and a therapeutic agent for dyslipidemia. The invention aims to provide an oligonucleotide that exhibits excellent binding affinity to the PCSK9 gene, ensuring stability and safety. This oligonucleotide features a sugar-modified nucleoside with a bridging structure between the 4'-position and the 2'-position, allowing it to effectively bind to the human PCSK9 gene. Additionally, the therapeutic agent incorporates this oligonucleotide as an active ingredient and preferably utilizes a bioabsorbable material, such as atelocollagen or peptide gel, as a carrier.
Career Highlights
Throughout his career, Narukawa has been associated with esteemed institutions, including Osaka University and the National Cerebral and Cardiovascular Center. His work in these organizations has allowed him to collaborate with leading researchers and contribute to advancements in medical science.
Collaborations
Some of Narukawa's notable coworkers include Satoshi Obika and Takeshi Imanishi. Their collaborative efforts have further enhanced the research and development of innovative therapeutic solutions.
Conclusion
Keisuke Narukawa's contributions to the field of biotechnology, particularly through his patent on oligonucleotides for dyslipidemia, highlight his role as a key innovator. His work continues to pave the way for advancements in therapeutic agents that target genetic conditions.